{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:08:03Z","timestamp":1776182883093,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.schres.2016.10.027","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T19:02:05Z","timestamp":1477335725000},"page":"90-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia"],"prefix":"10.1016","volume":"182","author":[{"given":"Eduardo","family":"Dunayevich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Nilsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Marder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.schres.2016.10.027_bb0005","first-page":"159","article-title":"The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia","volume":"25","author":"Alphs","year":"1989","journal-title":"Psychopharmacol. Bull."},{"issue":"2","key":"10.1016\/j.schres.2016.10.027_bb0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0165-1781(94)90086-8","article-title":"Factor structure of the negative symptom assessment","volume":"52","author":"Axelrod","year":"1994","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.schres.2016.10.027_bb0015","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1503\/cmaj.070693","article-title":"Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials","volume":"178","author":"Barbui","year":"2008","journal-title":"Can. Med. Assoc. J."},{"issue":"7","key":"10.1016\/j.schres.2016.10.027_bb0020","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2016.10.027_bb0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1600-0447.2007.01108.x","article-title":"Social functioning as an outcome measure in schizophrenia studies","volume":"116","author":"Burns","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"issue":"32","key":"10.1016\/j.schres.2016.10.027_bb0030","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.2174\/1381612819666140110121908","article-title":"NMDA pathology and treatment of schizophrenia","volume":"20","author":"Chang","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.schres.2016.10.027_bb0035","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1038\/mt.2014.126","article-title":"Population pharmacokinetic-pharmacodynamic (PKPD) modeling of AMG 747, a glycine transporter type 1 (Glyt1) inhibitor, in healthy subjects","author":"Chen","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.schres.2016.10.027_bb0040","first-page":"321","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol. Bull."},{"issue":"4","key":"10.1016\/j.schres.2016.10.027_bb0045","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881113512909","article-title":"Reviewing the ketamine model for schizophrenia","volume":"28","author":"Frohlich","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"7487","key":"10.1016\/j.schres.2016.10.027_bb0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature12929","article-title":"De novo mutations in schizophrenia implicate synaptic networks","volume":"506","author":"Fromer","year":"2014","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.schres.2016.10.027_bb0055","first-page":"1067","article-title":"Glycine modulators in schizophrenia","volume":"3","author":"Javitt","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.schres.2016.10.027_bb0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2016.10.027_bb0065","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","article-title":"The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization","volume":"165","author":"Kern","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2016.10.027_bb0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1755-5949.2010.00151.x","article-title":"Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades?","volume":"16","author":"Khan","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.schres.2016.10.027_bb0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.06.002","article-title":"Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia","volume":"66","author":"Kinon","year":"2013","journal-title":"Neuropharmacology"},{"issue":"3\u20134","key":"10.1016\/j.schres.2016.10.027_bb0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-003-1582-z","article-title":"NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development","volume":"169","author":"Krystal","year":"2003","journal-title":"Psychopharmacology (Berl.)"},{"issue":"1","key":"10.1016\/j.schres.2016.10.027_bb0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.schres.2016.10.027_bb0090","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archpsyc.62.11.1196","article-title":"Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"62","author":"Lane","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.10.027_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coph.2005.11.002","article-title":"Glutamate-based therapeutic approaches: inhibitors of glycine transport","volume":"6","author":"Lechner","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.schres.2016.10.027_bb0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.schres.2016.10.027_bb0105","first-page":"538","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychol."},{"issue":"2","key":"10.1016\/j.schres.2016.10.027_bb0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/arclin\/acp010","article-title":"Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex","volume":"24","author":"Maruff","year":"2009","journal-title":"Arch. Clin. Neuropsychol."},{"issue":"7","key":"10.1016\/j.schres.2016.10.027_bb0115","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/15622975.2014.989261","article-title":"Two phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy","volume":"16","author":"Moller","year":"2015","journal-title":"World J. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2016.10.027_bb0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2016.10.027_bb0125","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/13803390802592458","article-title":"A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia","volume":"31","author":"Pietrzak","year":"2009","journal-title":"J. Clin. Exp. Neuropsychol."},{"issue":"7","key":"10.1016\/j.schres.2016.10.027_bb0130","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s11136-005-2816-9","article-title":"Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients","volume":"14","author":"Ritsner","year":"2005","journal-title":"Qual. Life Res."},{"issue":"12","key":"10.1016\/j.schres.2016.10.027_bb0135","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","article-title":"Placebo response in antipsychotic clinical trials: a meta-analysis","volume":"71","author":"Rutherford","year":"2014","journal-title":"JAMA Psychiat."},{"issue":"7510","key":"10.1016\/j.schres.2016.10.027_bb0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium","year":"2014","journal-title":"Nature"},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2016.10.027_bb0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2016.10.027_bb0150","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/138161210790361452","article-title":"Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis","volume":"16","author":"Tsai","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.schres.2016.10.027_bb0155","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia","volume":"55","author":"Tsai","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.10.027_bb0160","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiat."},{"issue":"4","key":"10.1016\/j.schres.2016.10.027_bb0165","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14728222.5.4.507","article-title":"Glycine transport inhibitors as potential antipsychotic drugs","volume":"5","author":"Vandenberg","year":"2001","journal-title":"Expert Opin. Ther. Targets"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416304716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416304716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:50:53Z","timestamp":1536295853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416304716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":33,"alternative-id":["S0920996416304716"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.10.027","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}